HTRF assays run by HTRF experts
The first step in finding a drug candidate is usually to find a potential hit within a library.
Cisbio completes your work effectively by helping you follow-up, validate, and screen your hits.
Validating hits: We perform dose-response experiments to determine IC50/EC50 of a small compound collection with biochemical or cell-based assays, typically in a 384-well format.Assay examples include:
- GPCR: cAMP / IP-One, receptor-ligand binding
- Cell signaling assays
- cGMP for Phosphodiesterase (PDE) readout
Screening: Cisbio can screen small compound collections with any of our patented HTRF platforms, like IP-One for GPCR compound validation after Calcium flux in primary screening.
Comparability, stability, and lot release testing are important for developing biosimilars. Cisbio bioanalytical services for comparability studies include Fc binding on FcγR cell-based assays, and an FcRn assay for testing biosimilars. Take advantage of our extensive experience with biosimilar bioanalysis, including Bevacizumab, Trastuzumab, Rituximab, Etanercept, Adalimumab, Cetuximab, and Pertuzumab.